Bincy Abraham, MD, MS

  • Houston Methodist gastroenterologist
  • Inflammatory bowel disease program director, Houston Methodist Hospital Lynda K. and David M. Underwood Center for Digestive Disorders
  • Fondren Distinguished Professor in Inflammatory Bowel Disease, Houston Methodist Hospital Department of Medicine
  • Associate Professor of Clinical Medicine, Houston Methodist Institute for Academic Medicine

Bincy Abraham, MD, MS

Areas of Expertise

  • Capsule endoscopy
  • Clinical Trials
  • Crohn's disease
  • Pregnancy & inflammatory bowel disease
  • Transition of care in inflammatory bowel disease
  • Ulcerative colitis

Credentials

BOARD CERTIFICATION
Gastroenterology | American Board of Internal Medicine
FELLOWSHIP
Gastroenterology - University of Texas Medical Branch - Galveston, TX | 2008
RESIDENCY
University of Texas Medical Branch - Galveston, TX | 2005
INTERNSHIP
University of Texas Medical Branch - Galveston, TX | 2003
MEDICAL SCHOOL
University of Texas Medical Branch at Galveston | 2002

Publications

Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohn's Disease
Osterman, MT, Gordon, IO, Davis, EM, Ciorba, M, Glover, SC, Abraham, B, Khan, F, Guo, X, Yee, EU, Allard, FD, Claggett, B, Shen, B & Liu, JJ 2020, , Inflammatory bowel diseases, vol. 26, no. 10, pp. 1554-1561. https://doi.org/10.1093/ibd/izz222

The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study
Glassner, K, Oglat, A, Duran, A, Koduru, P, Perry, C, Wilhite, A & Abraham, BP 2020, Journal of Digestive Diseases, vol. 21, no. 5, pp. 264-271. https://doi.org/10.1111/1751-2980.12867


Antibiotics and probiotics in inflammatory bowel disease: When to use them?
Abraham, B & Quigley, EMM 2020, , Frontline Gastroenterology, vol. 11, no. 1, pp. 62-69. https://doi.org/10.1136/flgastro-2018-101057

The microbiome and inflammatory bowel disease
Glassner, KL, Abraham, BP & Quigley, EMM 2020, , Journal of Allergy and Clinical Immunology, vol. 145, no. 1, pp. 16-27. https://doi.org/10.1016/j.jaci.2019.11.003


Nanotechnology in the treatment of inflammatory bowel disease
Giron, F, Pastó, A, Tasciotti, E & Abraham, BP 2019, , Inflammatory bowel diseases, vol. 25, no. 12, pp. 1871-1880. https://doi.org/10.1093/ibd/izz205

The use of vedolizumab in pregnancy and breastfeeding in women with inflammatory bowel disease
Glassner, K & Abraham, BP 2019, Practical Gastroenterology, vol. 43, no. 9, pp. 13-18.

Fecal lactoferrin testing
Abraham, BP 2018, , Gastroenterology and Hepatology, vol. 14, no. 12, pp. 713-716.

Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis
Clinical Research Alliance of the Crohns and Colitis Foundation 2018, , Gastroenterology, vol. 155, no. 4, pp. 1098-1108.e9. https://doi.org/10.1053/j.gastro.2018.06.046

A Probiotic for Ulcerative Colitis: The Culture Wars Continue
Abraham, BP & Quigley, EM 2018, , Digestive Diseases and Sciences, vol. 63, no. 7, pp. 1678-1680. https://doi.org/10.1007/s10620-018-5097-1

Lack of placental transfer of certolizumab pegol during pregnancy: Results from CRIB, a prospective, postmarketing, pharmacokinetic study
Mariette, X, Förger, F, Abraham, B, Flynn, AD, Moltó, A, Flipo, RM, Van Tubergen, A, Shaughnessy, L, Simpson, J, Teil, M, Helmer, E, Wang, M & Chakravarty, EF 2018, , Annals of the Rheumatic Diseases, vol. 77, no. 2, pp. 228-233. https://doi.org/10.1136/annrheumdis-2017-212196

Engineered biomimetic nanovesicles show intrinsic anti-inflammatory properties for the treatment of inflammatory bowel diseases
Corbo, C, Cromer, WE, Molinaro, R, Toledano Furman, NE, Hartman, KA, De Rosa, E, Boada, C, Wang, X, Zawieja, DC, Agostini, M, Salvatore, F, Abraham, BP & Tasciotti, E 2017, , Nanoscale. https://doi.org/10.1039/c7nr04734g

Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease among Patients with Inflammatory Bowel Disease
Glassner, K, Malaty, HM & Abraham, BP 2017, , Inflammatory bowel diseases, vol. 23, no. 6, pp. 998-1003. https://doi.org/10.1097/MIB.0000000000001085

Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease
Sandborn, WJ, Wolf, DC, Kosutic, G, Parker, G, Schreiber, S, Lee, SD, Abraham, B, Afzali, A, Arsenescu, RI, Gutierrez, A, Spearman, M, Coarse, J & Feagan, BG 2017, , Inflammatory bowel diseases, vol. 23, no. 7, pp. 1047-1056. https://doi.org/10.1097/MIB.0000000000001100

Polymorphisms of 5-HTT LPR and GNß3 825C>T and Response to Antidepressant Treatment in Functional Dyspepsia: A Study from the Functional Dyspepsia Treatment Trial
Saito, YA, Locke, GR, Almazar, AE, Bouras, EP, Howden, CW, Lacy, BE, Dibaise, JK, Prather, CM, Abraham, BP, El-Serag, HB, Moayyedi, P, Herrick, LM, Szarka, LA, Camilleri, M, Hamilton, FA, Schleck, CD, Tilkes, KE, Zinsmeister, AR & Talley, NJ 2017, , American Journal of Gastroenterology, vol. 112, no. 6, pp. 903-909. https://doi.org/10.1038/ajg.2017.52

Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches
Abraham, BP, Ahmed, T & Ali, T 2017, . in B Greenwood-Van Meerveld (ed.), Gastrointestinal Pharmacology. vol. 239, Handbook of Experimental Pharmacology, vol. 239, Springer, pp. 115-146. https://doi.org/10.1007/164_2016_122

Probiotics in Inflammatory Bowel Disease
Abraham, BP & Quigley, EMM 2017, , Gastroenterology Clinics of North America, vol. 46, no. 4, pp. 769-782. https://doi.org/10.1016/j.gtc.2017.08.003

Ustekinumab as induction and maintenance therapy for Crohn's disease
UNITI-IM-UNITI Study Group 2016, , New England Journal of Medicine, vol. 375, no. 20, pp. 1946-1960. https://doi.org/10.1056/NEJMoa1602773


Languages

English